Search filters

List of works by Lisa Zimmer

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

scientific article

Checkpoint Inhibitors

article from 2019

Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients.

scientific article published on 13 February 2018

Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions

scientific article published on 18 May 2017

Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study

scientific article published on 13 November 2019

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

scientific article published on 8 October 2012

Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy

scientific article published on 18 February 2016

Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients

scientific article published on 01 October 2020

Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG

scientific article published on 01 May 2020

Incidence of new primary melanomas after diagnosis of stage III and IV melanoma.

scientific article published on 2 December 2013

Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival

scientific article

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma

scientific article published on 16 February 2017

Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders

scientific article published on 27 February 2018

Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma

scientific article

Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors

scientific article published on 17 November 2018

Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD-1-Antikörper beim metastasierten Melanom - ein Update

scientific article published on 01 June 2020

Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD1-Antikörper beim metastasierten Melanom

Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.

scientific article

Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)

scientific article published on 21 November 2020

Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity

scientific article published on 16 February 2017

Reply to M. Perier-Muzet et al

scientific article published on 02 September 2014

Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update

scientific article published on 03 June 2020

TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma

scientific article

Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations

scientific article published on 03 October 2019

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

scientific article

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ⬇️

scientific article published on 23 May 2019

Use of complementary medicine in metastatic melanoma patients treated with ipilimumab within a clinical trial

scientific article

Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study

scientific article published on 10 April 2020

Paulina is supported by:

About Paulina

Help